Physician profile
Robert Dean Okada
NPI 1003816877
$3,044.83
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $509 · 2021: $454 · 2022: $382.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $438.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $432.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $235.95 | 2019-2022 | |
| Boston Scientific Corporation | $207.27 | 2019-2022 | |
| Abbott Laboratories | $201.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $158.56 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $125.74 | 2019 | |
| Pfizer INC. | $118.74 | 2019-2022 | |
| Amarin Pharma, INC. | $114.33 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $105.78 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.66 | 2019-2022 | |
| Biotronik INC. | $91.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $91.35 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $72.26 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.75 | 2021-2022 | |
| Esperion Therapeutics, INC. | $66.49 | 2021-2022 | |
| Lundbeck LLC | $52.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.20 | 2020 | |
| Biosense Webster, INC. | $21.74 | 2019 | |
| Nuwellis, INC. | $17.23 | 2020 | |
| Philips North America LLC | $16.55 | 2022 | |
| Medtronic Vascular, INC. | $14.41 | 2019 | |
| Chiesi USA, INC. | $14.10 | 2021 | |
| Portola Pharmaceuticals, LLC | $13.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Okada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.